Primary Effusion Lymphoma (PEL): A distinct B-cell lymphoma presenting predominantly as malignant effusions in body cavities, often linked to HHV8 infection and immunodeficiency.

Primary Effusion Lymphoma: A rare B-cell malignancy predominantly presenting as lymphomatous effusions in serous cavities without an associated solid tumour mass, often linked to HHV8 infection.

e19089Background: Primary effusion lymphoma (PEL) represents a small proportion of non-Hodgkin lymphomas, historically associated with human immunodeficiency virus (HIV) infection. Despite this, ...

A 34-year-old man was admitted to the hospital because of left ear pain with hearing loss and facial droop on the left side. Computed tomography showed a nasopharyngeal mass. A diagnosis was made.

Citius Oncology has completed commercial-scale manufacturing of LYMPHIR, with packaged and labeled inventory now held at a leading global Contract Development and Manufacturing Organization (CDMO).

Primary effusion lymphoma in human immunodeficiency virus (HIV)–negative population: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in ...

Roche has demonstrated the power of combining two of oncology’s hottest modalities—bispecifics and antibody-drug conjugates ...

The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with ...

The Food and Drug Administration (FDA) has approved Monjuvi ® (tafasitamab-cxix), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory (R/R) ...

Adding tafasitamab to treatment with lenalidomide and rituximab improved outcomes in patients with relapsed or refractory follicular lymphoma.

Cancer of unknown primary site is an uncommon diagnosis that accounts for 2 to 4% of all cancers. 9 The American Cancer Society estimates that approximately 37,370 new cases of cancer of unknown ...